Ftse Mib
34.396,01
0,06%
DAX
18.518,03
-0,44%
S&P 500
5.651,55
0,36%
NASDAQ
18.468,64
-0,02%
Bitcoin
64.952,87
0,16%
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Blueprint Medicines Corporation (BPMC) Blueprint Medicines Corporation (BPMC) Notizie

BPMC

Blueprint Medicines (BPMC)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:BPMC
DataOraFonteTitoloSimboloCompagnia
04/05/202313:00PR Newswire (US)Blueprint Medicines Reports First Quarter 2023 ResultsNASDAQ:BPMCBlueprint Medicines Corporation
01/05/202312:04Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:BPMCBlueprint Medicines Corporation
28/04/202323:35Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:BPMCBlueprint Medicines Corporation
26/04/202316:00PR Newswire (US)Blueprint Medicines to Present New Clinical Data Across Broad Precision Therapy Pipeline at 2023 ASCO Annual MeetingNASDAQ:BPMCBlueprint Medicines Corporation
20/04/202322:01PR Newswire (US)Blueprint Medicines to Report First Quarter 2023 Financial Results on Thursday, May 4, 2023NASDAQ:BPMCBlueprint Medicines Corporation
11/04/202314:00PR Newswire (US)Blueprint Medicines to Present at Upcoming Investor ConferencesNASDAQ:BPMCBlueprint Medicines Corporation
05/04/202322:01PR Newswire (US)Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BPMCBlueprint Medicines Corporation
28/03/202323:05Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:BPMCBlueprint Medicines Corporation
28/03/202322:05PR Newswire (US)Blueprint Medicines Announces Lift of Partial Clinical Hold on Phase 1/2 VELA Trial of BLU-222NASDAQ:BPMCBlueprint Medicines Corporation
26/02/202321:00PR Newswire (US)Blueprint Medicines Presents Registrational Data from PIONEER Trial of AYVAKIT® (avapritinib) in Patients with Indolent Systemic Mastocytosis at 2023 AAAAI Annual MeetingNASDAQ:BPMCBlueprint Medicines Corporation
23/02/202314:00PR Newswire (US)Blueprint Medicines to Regain Global Rights to GAVRETO® (pralsetinib) from RocheNASDAQ:BPMCBlueprint Medicines Corporation
17/02/202314:13Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:BPMCBlueprint Medicines Corporation
17/02/202314:08Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:BPMCBlueprint Medicines Corporation
17/02/202313:38Edgar (US Regulatory)Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr)NASDAQ:BPMCBlueprint Medicines Corporation
16/02/202323:26Edgar (US Regulatory)Annual Report (10-k)NASDAQ:BPMCBlueprint Medicines Corporation
16/02/202313:00PR Newswire (US)Blueprint Medicines Reports Fourth Quarter and Full Year 2022 ResultsNASDAQ:BPMCBlueprint Medicines Corporation
14/02/202318:41Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:BPMCBlueprint Medicines Corporation
10/02/202314:49Dow Jones NewsBlueprint Medicines BLU-222 Study on FDA Partial HoldNASDAQ:BPMCBlueprint Medicines Corporation
10/02/202314:00PR Newswire (US)Blueprint Medicines Announces Partial Clinical Hold for Phase 1/2 VELA Trial of BLU-222NASDAQ:BPMCBlueprint Medicines Corporation
09/02/202314:00PR Newswire (US)Blueprint Medicines to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023NASDAQ:BPMCBlueprint Medicines Corporation
06/02/202320:50Edgar (US Regulatory)Schedule 13g
(sc 13g/a)		NASDAQ:BPMCBlueprint Medicines Corporation
03/02/202315:00PR Newswire (US)Blueprint Medicines to Present Positive Data from PIONEER Trial of AYVAKIT® (avapritinib) in Indolent Systemic Mastocytosis at 2023 AAAAI Annual MeetingNASDAQ:BPMCBlueprint Medicines Corporation
23/01/202314:51Dow Jones NewsBlueprint Medicines Gets FDA Priority Review for Ayvakit in Indolent Systemic MastocytosisNASDAQ:BPMCBlueprint Medicines Corporation
23/01/202314:00PR Newswire (US)Blueprint Medicines Announces FDA Acceptance of Supplemental New Drug Application for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic MastocytosisNASDAQ:BPMCBlueprint Medicines Corporation
09/01/202323:17Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:BPMCBlueprint Medicines Corporation
09/01/202323:14Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:BPMCBlueprint Medicines Corporation
06/01/202315:00PR Newswire (US)Blueprint Medicines Appoints John Tsai, M.D. to its Board of DirectorsNASDAQ:BPMCBlueprint Medicines Corporation
05/01/202314:00PR Newswire (US)Blueprint Medicines Provides 2023 Portfolio Goals to Achieve Precision at ScaleNASDAQ:BPMCBlueprint Medicines Corporation
12/12/202212:15TipRanksBerenberg Bank Sticks to Its Buy Rating for Blueprint Medicines (BPMC)NASDAQ:BPMCBlueprint Medicines Corporation
22/11/202222:36PR Newswire (US)Blueprint Medicines Submits Supplemental New Drug Application to FDA for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic MastocytosisNASDAQ:BPMCBlueprint Medicines Corporation
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:BPMC

La tua Cronologia

LSE
FTE
LSE
CSPX
Ishrc S&p 500
NYSE
COF
Capital One Financial
BIT
FLOT
Exchange Traded
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network